Please provide your email address to receive an email when new articles are posted on . AACE published its first updated guideline on the pharmacologic management of adults with dyslipidemia since ...
Choices for pharmacologic therapy should be guided by a 10-year global risk assessment score for ASCVD or coronary heart disease using established risk equations (eg, the Framingham risk calculator, ...
Individuals who achieved a BMI of less than 25 kg/m2 in the SURMOUNT trials of tirzepatide also experienced significant ...
Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify ...
The American College of Cardiology (ACC) has released an Expert Consensus Decision Pathway (ECDP) to provide guidance on treating and managing patients with atherosclerotic cardiovascular disease ...
Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events in patients with and without preexisting atherosclerotic cardiovascular disease (ASCVD), a new study shows. The ...
—Recent studies suggest that a hospitalization related to cardiovascular events can follow a hospitalization for chronic obstructive pulmonary disease. But have these studies been too broad? No ...
The results of a recent retrospective analysis of patients with established atherosclerotic cardiovascular disease (ASCVD) demonstrated that prior testing for lipoprotein(a) (Lp[a]) was associated ...
Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events. A new analysis of the Family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results